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Orsetta Zuffardi6 and Mauro Bozzola2,7*Abstract
We report on a male child ascertained at 4.8 years of age with severe growth failure, growth hormone (GH)
deficiency, psychomotor delay with prevalent speech impairment, and a distinct phenotype. An evaluation of his
hypothalamic-pituitary region by Magnetic Resonance Imaging (MRI) revealed pituitary hypoplasia with pituitary
stalk interruption and ectopic posterior pituitary lobe, which are considered prognostic markers of permanent GH
deficiency. Prenatal chromosome analysis because of increased nuchal translucency revealed a normal male karyo-
type, whereas postnatal high resolution banding raised the suspicion of a 2q abnormality. Subsequently, array Com-
parative Genomic Hybridization (array-CGH) revealed a de novo complex genomic rearrangement consisting of a
2p25 duplication and a 2q37 deletion: arr[hg19] 2p25.3p25.1(30,341-9,588,369)x3,2q37.2q37.3(235,744,424-
243,041,305)x1. FISH analysis showed that the abnormal chromosome 2 mimicked the derivative of an inversion
with the duplicated 2p region located distally at 2q. This is, to the best of our knowledge, the first case with distal
2p25 duplication and 2q37 deletion and pituitary malformation leading to GH deficiency.
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The overall frequency of sub-microscopic causative dele-
tions and duplications detected by chromosomal micro-
arrays (CMA) in patients with intellectual disability/
multiple congenital malformations, is around 15-20%,
significantly higher in respect to that provided by con-
ventional karyotyping [1].
Chromosome 2q37 deletion has been reported in more
than 100 patients most of whom display short stature,
obesity, brachydactily and intellectual deficiency, which
are also observed in Albright syndrome [2]. The HDAC4
gene has notably been established as responsible for bra-
chymetaphalangy and intellectual deficit observed in
these individuals [2,3]. Distal 2p duplication has also* Correspondence: mauro.bozzola@unipv.it
†Equal contributors
2Department of Internal Medicine and Therapeutics, Pediatric and
Adolescent Unit, University of Pavia, Fondazione IRCCS San Matteo, Pavia,
Italy
7Internal Medicine and Therapeutics Department, University of Pavia,
Fondazione IRCCS San Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
Full list of author information is available at the end of the article
© 2014 Vetro et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.been reported although much more rarely and mostly in
the context of inv dup 2p syndrome [4,5]. The clinical
phenotype includes pre- and post-natal growth retard-
ation, psychomotor delay, facial dysmorphism and, less
frequently congenital heart malformations. To our
knowledge only three subjects have been reported to
have both the 2q deletion and 2p duplication two result-
ing de novo and one being the derivative of a maternal
pericentric inversion [6,7]. Due to the complexity of the
chromosomal rearrangement and its rarity, a clinical
diagnosis of this condition is almost impossible. Here,
we report on a four year-old child harboring a de novo
2p25 duplication and 2q37.1-qter deletion presenting
with severe psychomotor delay and complete GH defi-
ciency due to pituitary hypoplasia. The molecular diag-
nosis had been significantly delayed since prenatal
cytogenetics analysis, performed to investigate increased
fetal nuchal translucency, resulted in a normal male
karyotype. As a consequence, the patient’s condition in
his early infancy was attributed to a Mendelian
syndrome.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Patient’s images. A) Patient at of 7.5 years showing facial
characteristics including right palpebral ptosis, low set ears, and
small mouth with thin upper lip. B) Patient’s hands
showing brachymetaphalangism.
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The propositus was the second child of healthy non-
consanguineous Italian parents. His father and mother
were 40 and 37 years old, respectively. Ultrasound scan
at the 22nd week of gestation revealed an increased fetal
nuchal translucency, while the amniocentesis showed a
normal 46,XY fetal karyotype. The patient was born at
term (40 weeks) by spontaneous vaginal delivery. The
birth weight was 3340 g (0.51 SD), birth length 50 cm
(0.53 SD), and OFC 36 cm (0.50 SD). Apgar scores were
9 and 9 at 1 and 5 minutes, respectively. Family history
was unremarkable. The father’s height was 165.8 cm and
the mother’s height was 148.5 cm with a mid-parental
height of 163.5 cm. His eight year-old sister was healthy.
At four months of age the parents noted the presence
of axial hypotonia. When first seen at one year of age,
he was noted to have dysmorphic features, including
micro-brachycephaly due to premature closure of the
anterior fontanelle, prominent forehead, up-slanting pal-
pebral fissures, low set ears and sparse hair. Brain ultra-
sound was normal. All developmental milestones were
delayed: he achieved head control at five months of age,
sat unaided at nine months, and walked at 21 months.
He was able to speak in complete sentences at four
years. Because of a systolic murmur, at the age of three
months a cardiac ultrasound examination revealed a mi-
tral valve dysplasia with valve insufficiency, not requiring
surgical repair. He underwent speech therapy sessions
because of a mild perceptive hypoacusia found at four
months.
On physical examination at the age of 4.8 years his
height was 89.1 cm (−4.05 SD), his weight was 11.9 kg
(−0.57 SD), OFC was 48 cm (−1 SD) and growth velocity
was reduced for age (4 cm/year, i.e. -2.1 SD). He pre-
sented a characteristic phenotype including slight trigo-
nocephaly, right palpebral ptosis, low set ears, small
mouth with a thin upper lip and micrognathia (Fig-
ure 1A), with small hands and feet with fleshy fingertips,
brachymetaphalangism (Figure 1B), bilateral single pal-
mar creases, short neck and scoliosis. Chronic diseases
including intestinal malabsorption, celiac disease, consti-
tutional skeletal diseases and hypothyroidism were ex-
cluded. Two pharmacological stimulus tests with
arginine chlorohydrate and glucagon revealed a severe
growth hormone (GH) deficiency (peak of 1.7 and 2 ng/
ml, respectively), confirmed by IGF-I values: <25 ng/ml
(−3.49 SD) that increased to 62.7 ng/ml after four sub-
cutaneous GH injections suggesting good responsiveness
to GH treatment (0.24 mg/Kg/week). No other pituitary
hormone deficiencies were found to be associated. A
brain MRI was performed with sagittal and coronal
3 mm-thick T1- and T2-weighted images for the
hypothalamic-pituitary region, revealing pituitary hypo-
plasia, pituitary stalk interruption and an ectopicposterior pituitary lobe (Figure 2A). Additionally, a small
focal nonspecific T2 hyperintensity was noted in the
right globus pallidus that was unchanged at a 6-month
brain MRI follow-up (Figure 2B). Substitutive GH ther-
apy was started and led to a significant growth velocity
increase as shown in Figure 3. In fact, after the first year
of treatment, his height was 100 cm (−2.84 SD) and
weight 15 Kg (−0.66 SD) with a significant increase in
growth velocity to 8.5 cm/yr (+2.51 SD). After the sec-
ond year of GH therapy, his height and weight were
107.9 cm (−2.31 SD) and 17.5 Kg (−0.77 SD) respect-
ively, with a significant increase in his growth rate to
7.9 cm (+3.04 SD).
Because of facial dysmorphisms, mitral valve dysplasia,
growth failure and mild developmental delay, Noonan
syndrome was considered in the differential diagnosis.
However, the sequencing of the PTPN11 gene, the
PTPN11 gene, whose mutations can explain about 50%
of cases of Noonan syndrome [8], did not disclose any
alteration. Since the prenatal karyotype resulted to be
normal, a high-resolution banding karyotype was re-
quested, and an abnormality at the distal long arm of
one chromosome 2 was observed (Figure 4A). To
characterize the rearrangement, array-CGH analysis was
Figure 2 Brain MRI of the patient at 4.8 years. A) Unenhanced midline sagittal T1-weighted image shows hyperintensity corresponding to ec-
topic posterior pituitary lobe at the median eminence (arrowhead). The pituitary gland and sella turcica are small, and the pituitary stalk is not vis-
ible (white arrow). B) Axial FLAIR image reveals a small nonspecific hyperintense lesion in the right globus pallidus (black arrow).
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gies, Santa Clara, CA) [9]. A call for copy number vari-
ation (CNV) was done by at least three consecutive
probes with a log2ratio value significantly different from
0, by using Genomic Workbench v. 5.0.14 software (Agi-
lent, ADM-2 algorithm with a threshold of 5). This ana-
lysis showed a complex genomic imbalance consisting of
a 2p25 distal duplication of about 9.6 Mb and a 2q37
distal deletion of about 7.3 Mb, containing 26 and 61
protein coding genes respectively: arr[hg19] 2p25.3p25.1
(30,341-9,588,369)x3,2q37.2q37.3(235,744,424-
243,041,305)x1 (Figure 4B-D). Fluorescent In Situ
Hybridization (FISH) analysis, performed with subtelo-
meric chromosome 2 specific probes (VIJyRM2052 for
2p; D2S447 for 2q, both from Vysis TelVysion, Abbott
Molecular, Abbott Park, IL) confirmed the presence of
the two imbalances and showed that the duplicated 2p
region was located distally at 2 q (Figure 4C). Since the
rearrangement was detectably by high-resolution band-
ing, the same karyotype analysis was performed on par-
ental blood samples showing that the rearrangement was
de novo.
Conclusion
Both 2p duplications and 2q deletions are usually ob-
served as part of more complex duplication/deletion
syndromes, being distal imbalances frequently associated
with the unbalanced segregation of a reciprocal trans-
location present in one parent or, more rarely, arisen de
novo in the early embryo. Obviously, the presence of
two different imbalances, involving several genes at
once, makes clear genotype-phenotype correlations moredifficult and renders the recognition of the syndrome on
clinical grounds almost impossible. Complex rearrange-
ments involving a terminal short arm duplication and a
terminal long arm deletion of the same chromosome
may result from meiotic recombination of a parental
pericentric inversion as in one patient reported by Arm-
strong et al., 2005 [6]. However many of these cases are
the result of a de novo event [10], suggesting that the re-
arrangement may occur in two steps, the first resulting
in a terminal deletion lately repaired by the capture of
the telomere of the opposite arm, thus resulting in its
duplication [9,11]. In our case both parents had a nor-
mal karyotype, suggesting that the rearrangement most
likely occurred through this mechanism.
In the literature only three viable patients with both a
short arm duplication and long arm deletion of chromo-
some 2 have been reported [6,7], two of them sharing
with our patient short stature, mild trigonocephaly, pto-
sis, low set ears, micrognathia, fleshy fingertips, scoliosis
and abnormal hearing [6]. In the third case, in which the
extent of 2p duplication was not assessed, developmental
delay, short stature and dolichocephaly were reported
[7]. Phenotypic findings in patients with chromosome 2q
terminal deletions correlate in some cases with break-
points positions [2,12], although in many cases geno-
type–phenotype correlations have been impaired by the
lack of molecular analysis or by the presence of a trans-
location derivative. However, almost all patients have
moderate to severe developmental delay, short stature,
obesity and brachymetaphalangy [2,12,13]. The latter,
together with short stature, is characteristic of the
Albright’s hereditary osteodystrophy-like (AHO-like)
Figure 3 Patient’s growth chart. In the figure height measurements from birth to 7.5 years are reported.
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ciency for the HDAC4 (Histone deacetylase 4) gene has
been proposed as responsible for the observed brachy-
metaphalangy and intellectual disability, with both dele-
tions and truncating mutations reported in association
to this phenotype [3]. Although short stature seems to
be a common trait for both 2q terminal deletions or 2p
distal duplications, the presence of associated endocrino-
logical defects has been rarely reported, and we are
aware of only two reports of GH-deficiency in patients
with a 2q37 deletion [13,14]. We were not able to find
any cases of pituitary stalk interruption in patients with
similar rearrangements, either searching the literature orin public databases such as DECIPHER [15]. In our patient
26 and 61 protein coding genes are respectively duplicated
or deleted. Even using prioritization tools (Endeavour [16],
ToppGene [17]), we were not able to find a convincing
candidate for his pituitary defect. Moreover, no pituitary-
specific expression is reported for any of the candidates.
We can speculate that in the non-deleted chromosome, a
gene necessary for the proper pituitary development is
mutated, possibly unmasking a recessive condition.
In conclusion, this is the first case of distal 2p duplica-
tion and 2q deletion with severe short stature and pituit-
ary hypoplasia, interrupted pituitary stalk and an ectopic
posterior pituitary lobe. These findings are considered
Figure 4 Karyotype, array-CGH analysis, FISH analysis. A) Cut-out of chromosomes 2 from two metaphases. The der(2) are highlighted by the
arrows. B) Array-CGH profile of patient’s chromosome 2 showing the 2p distal duplication (upper panel in the enlargement) and the concurrent
2q distal deletion (lower panel in the enlargement). The experiment was performed by using a 180 K platform (180 K SurePrint G3 Human Kit,
Agilent Technologies, Santa Clara, CA) as reported elsewhere [8]. C) FISH analysis with subtelomeric chromosome 2 specific probes (VIJyRM2052
in green, 2p; D2S447, in red, 2q; (Vysis TelVysion, Abbott Molecular, Abbott Park, IL) shows green signals at both extremities of the rearranged
chromosome 2 (yellow arrow), flanked by its normal homolog. D) The protein-coding genes included in the duplication (upper panel) and the
deletion (lower panel) are reported, according to UCSC Genome Browser (http://genome-euro.ucsc.edu/).
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tected in our patient and may be associated with other
hormonal defects causing variably severe panhypopitui-
tarism [18] not present in our case. The diagnosis of GH
deficiency was confirmed by the significant increase in
growth rate after substitutive GH therapy.
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